After the study regimen was initiated, urine output and fluid balance, vital statistics, labs, and samples for biomarkers were ob- tained at 8, 24, 48, 72, and 96 h, respectively. Patient self-reported dyspnoea (7-point Likert scale) was also ob- tained verbally by a study coordinator at 24 and 96 h (or when the study regimen was discontinued if prior to 96 h) using a set script. Patient-reported or physician reported adverse events were noted if they occurred. Study proceduretiming is outlined in Supporting Information, Figure SS1.